Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$194M in Q4 2019 → — now. Hover for any quarter.
As reported for the quarter ended June 30, 2020. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| 0 0 | NaN% | New | 0 | — |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2020 · filed July 07, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Theravance Biopharma, Inc. | Exited | −4,836,864 | −$111M | — |
| Evofem Biosciences, Inc. | Exited | −9,138,504 | −$45.5M | — |
| 0 0 | New | +0 | — | — |
quarter ended March 31, 2020 · filed April 16, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Theravance Biopharma, Inc. | Trimmed | −414,485 | −$9.54M | 71.0% |
Loading...
